Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edin Basic

Internal Medicine Clinton Township, MI Doctor of Osteopathy

NPI 1124206685 CMS profile 96828

15855 19 Mile Rd, Clinton Township, MI 48038

Open in the dashboard

General payments

$9,633

401 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edin Basic of Clinton Township, MI is reported in the CMS Open Payments database as having received $9,633 across 401 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,512 60
2024 General $2,677 90
2023 General $1,951 85
2022 General $1,697 72
2021 General $939 52
2020 General $538 25
2019 General $320 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edin Basic
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Edin Basic were reported at $1,512. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Edin Basic Internal Medicine median Middle half National median
2019 $320 $159 $48–$570 $163
2020 $538 $119 $33–$402 $114
2021 $939 $135 $37–$521 $132
2022 $1,697 $141 $42–$496 $149
2023 $1,951 $149 $45–$519 $160
2024 $2,677 $154 $47–$537 $164
2025 $1,512 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $995 42 payments
  2. Calliditas Therapeutics US Inc. $762 26 payments
  3. Relypsa, Inc. $733 35 payments
  4. Mallinckrodt Hospital Products Inc. $719 25 payments
  5. ANI Pharmaceuticals, Inc. $704 25 payments
  6. Retrophin, Inc. $704 10 payments
  7. AstraZeneca Pharmaceuticals LP $669 34 payments
  8. Horizon Therapeutics plc $625 29 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $598 40 payments
  10. Otsuka America Pharmaceutical, Inc. $546 22 payments
  11. Other $2,578 113 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,854 385 payments
  2. Education $404 14 payments
  3. Consulting Fee $375 2 payments
Products named General payments · program years 2019–2025
  1. ACTHAR $719 25 payments
  2. KRYSTEXXA $625 29 payments
  3. Kerendia $598 40 payments
  4. TAVNEOS $522 19 payments
  5. JYNARQUE $463 19 payments
  6. Veltassa $453 21 payments
  7. FARXIGA $443 21 payments
  8. PURIFIED CORTROPHIN GEL $400 12 payments
  9. TARPEYO Nephrology $385 11 payments
  10. TARPEYO Nephrology $339 13 payments
  11. Other $4,172 184 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

916

Median for Nephrology: 954

Drug cost

$380,682

Median for Nephrology: $127,050

Branded share of claims

20.7%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jynarque Tolvaptan Brand 15 $285,263
Farxiga Dapagliflozin Propanediol Brand 56 $43,731
Jardiance Empagliflozin Brand 32 $26,980
Ozempic Semaglutide Brand 13 $13,345
Olmesartan-Amlodipine-Hctz Olmesartan/Amlodipin/Hcthiazid Brand 14 $1,567
Febuxostat Generic 21 $1,422
Hydralazine Hcl Generic 64 $1,275
Losartan Potassium Generic 121 $907
Nifedipine Er Nifedipine Brand 20 $901
Calcitriol Generic 56 $781

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$126,334

Medicare's payments for the services billed

Medicare patients

216

Average age 71

Services billed

1,786

101 women, 115 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Arthritis 60%
Diabetes 57%
Ischemic heart disease 46%
Heart failure 43%
Atrial fibrillation 37%
Depression 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $228
  • Lilly USA, LLC $59
$287 32 —
TARPEYO
  • CALLIDITAS THERAPEUTICS US INC. $275
$275 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $231
$231 — —
TAVNEOS
  • Amgen Inc. $221
$221 — —
JYNARQUE
  • Otsuka America Pharmaceutical, Inc. $172
$172 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

401 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record